Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antibiotics >  Macrolides >  ROKITAMYCIN

ROKITAMYCIN

Basic information Safety Supplier Related

ROKITAMYCIN Basic information

Product Name:
ROKITAMYCIN
Synonyms:
  • 3''-Propionylleucomycin A5
  • Leucomycin V, 4B-butanoate 3B-propanoate (9CI)
  • Ricamycin
  • TMS 19Q
  • ROKITAMYCIN
  • Leummycin V 4B-bu-tanoate 3 B-propanoate
  • M-19-Q
  • Rikamycin
CAS:
74014-51-0
MF:
C42H69NO15
MW:
827.99
Mol File:
74014-51-0.mol
More
Less

ROKITAMYCIN Chemical Properties

Melting point:
116°
alpha 
D20 -71° (c = 1.0 in chloroform)
Boiling point:
879.3±65.0 °C(Predicted)
Density 
1.21±0.1 g/cm3(Predicted)
storage temp. 
Inert atmosphere,Store in freezer, under -20°C
pka
13.06±0.70(Predicted)
CAS DataBase Reference
74014-51-0
More
Less

ROKITAMYCIN Usage And Synthesis

Description

Rokitamycin is a semisynthetic macrolide antibiotic, closely related to miokamycin(2) both in structure and antimicrobial spectrum.

Originator

Toyo Jozo (Japan)

Definition

ChEBI: Rokitamycin is an organic molecular entity.

brand name

RICAMYCIN

Pharmaceutical Applications

3″-Propionyl leucomycin A5. A semisynthetic macrolide. Unstable in acid media.
The antibacterial spectrum is identical to that of erythromycin, but it is less active against Gram-positive cocci. It is poorly active against H. influenzae (MIC50 8 mg/L) and Mor. catarrhalis (MIC50 4 mg/L). It displays good activity against Campylobacter spp. (MIC50 0.1 mg/L), L. pneumophila (MIC50 0.1 mg/L) and M. pneumoniae (MIC50 0.003 mg/L). It is active against anaerobes, including some Bacteroides spp. (MIC50 <0.05 mg/L).
After a single oral dose of 600 mg, the peak plasma concentration was 1.9 mg/L after 0.6 h. Oral doses of 5, 10 and 15 mg/kg of a syrup formulation given to children achieved plasma concentrations of 0.26, 0.55 and 0.79 mg/L, respectively, after about 40 min. The half-life is around 2 h.
It is mainly eliminated in the bile; only about 2% appears in the urine. Its major metabolites are leucomycin A7, 10″-OH-rokitamycin (which show some antibacterial activity) and leucomycin V. In healthy adult volunteers, the proportions of rokitamycin and its metabolites in serum 30 min after a single oral dose of 1200 mg were 18% (leucomycin A7), 33% (10″-OH-rokitamycin) and 9% (leucomycin V). The pharmacokinetic behavior is not altered in patients with liver cirrhosis. It is available in Italy and Japan.

ROKITAMYCINSupplier

Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Email
waley188@sohu.com
Shanghai Han-Xiang Chemical Co., Ltd.
Tel
15971444841
Email
amber@biochempartner.com
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Dideu Industries Group Limited
Tel
+86-29-89586680 +86-15129568250
Email
1026@dideu.com
Shaanxi Dideu Medichem Co. Ltd
Tel
+86-029-89586680 +86-18192503167
Email
1026@dideu.com